Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Once-daily formulation of paroxetine submitted for FDA review

March 3, 1998

Milestone reached in Corvas/Pfizer NIF collaboration

March 3, 1998

Antioxidant and neuroprotective effects of GSNO confirmed

March 2, 1998

Canadian approval obtained for Mirapex

Feb. 27, 1998

Antimigraine agents with reduced liability for side effects developed at MS&D

Feb. 27, 1998

AIT-082 enters multidose study

Feb. 27, 1998

Rizatriptan approved in The Netherlands

Feb. 27, 1998

First NDA filing for Sonata

Feb. 26, 1998

IL-6 suggested to be an endogenous neuroprotective factor

Feb. 26, 1998

SSRIs appear safe for use during pregnancy

Feb. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...